Browse the evidence

Tirzepatide use is associated with novel safety signals including belching, upper respiratory tract infections, and postmenopausal hemorrhage, which are not prominently featured in standard prescribing information.

Be aware that Tirzepatide may be linked to new symptoms not always listed in official documents, such as excessive belching, respiratory infections, or unusual bleeding (especially in postmenopausal women). Report these to your healthcare provider, as they are emerging safety signals.

GLP-1 receptor agonist use may improve specific inflammatory or scarring alopecias (e.g., Folliculitis Decalvans, Central Centrifugal Cicatricial Alopecia) through metabolic modulation and anti-inflammatory effects.

If you have a specific type of hair loss like Folliculitis Decalvans or Central Centrifugal Cicatricial Alopecia, and you are prescribed a GLP-1 agonist for weight or diabetes, it might actually help your hair regrow by improving blood flow and reducing inflammation. This is not guaranteed for everyone, but it is a documented possibility in case studies.

Tirzepatide exacerbates orthostatic intolerance and causes marked tachycardia in patients with Postural Orthostatic Tachycardia Syndrome (POTS).

If you have POTS and are considering tirzepatide, discuss your specific heart rate response risks with your doctor. This case suggests that standard dosing might cause severe tachycardia in POTS patients, so a lower starting dose (e.g., 2.5 mg) and close monitoring of heart rate and orthostatic symptoms are critical to prevent exacerbation.

Tirzepatide use is associated with a potential risk of acute deep vein thrombosis (DVT), particularly in patients with predisposing risk factors such as obesity, rapid weight loss, or dehydration.

If you are taking tirzepatide, be aware of signs of blood clots like swelling, pain, or redness in your arms or legs. While rare, this risk exists, especially if you are losing weight rapidly or are obese. Report these symptoms to your doctor immediately.

Tirzepatide may trigger new-onset atrial fibrillation in susceptible individuals through autonomic activation and sinoatrial node effects, despite its overall cardiometabolic benefits.

If you start tirzepatide and feel palpitations, lightheadedness, or a racing heart, seek medical attention promptly. While the drug improves long-term metabolic health, it can increase heart rate and potentially trigger atrial fibrillation in susceptible individuals. Do not ignore new cardiac symptoms.

Coadministration of tirzepatide and SGLT2 inhibitors in Type 1 Diabetes Mellitus patients significantly increases the risk of severe euglycemic diabetic ketoacidosis (euDKA), potentially requiring mechanical ventilation.

If you have Type 1 Diabetes, do not take Tirzepatide or SGLT2 inhibitors together without extreme caution and specialist oversight. Monitor ketones daily, especially if you feel nauseous or vomit, as blood sugar may remain normal while dangerous acidosis builds up.

Natural peptides (BRP, BPC-157, MOTS-c) offer a safer, more metabolically specific alternative to semaglutide for obesity management by preserving lean mass and avoiding severe gastrointestinal side effects.

Natural peptides like BRP, BPC-157, and MOTS-c are emerging as potential alternatives to semaglutide, offering weight loss with better preservation of muscle mass and fewer gastrointestinal side effects. However, current evidence is limited to animal studies. Patients should consult healthcare providers regarding the safety, dosage, and regulatory status of these peptides, as they are not yet standard FDA-approved treatments for obesity.

Acute administration of GLP-1 receptor agonists reduces brain reactivity (BOLD response) to food-related cues in reward and salience regions, whereas long-term administration effects are inconsistent or attenuate over time.

GLP-1 medications appear to reduce the brain's intense reaction to food cues, particularly when taken acutely. However, this neural dampening may not persist or may vary significantly with long-term use. The evidence is currently limited and inconsistent, so while the mechanism suggests reduced craving, individual responses to long-term cue reactivity reduction are not guaranteed.

Neurokinin 2 receptor (NK2R) activation reduces appetite and body weight in mice without the gastrointestinal side effects associated with GLP-1 based treatments.

Research is exploring new drugs that target Neurokinin 2 Receptors (NK2R) to suppress appetite without causing the nausea common with current GLP-1 drugs. These are currently only proven effective in mice, so they are not yet available for human use.

Tirzepatide can cause direct drug-induced liver injury (hepatitis) independent of gallbladder disease, characterized by elevated liver enzymes and bilirubin that normalize upon discontinuation.

If you are taking Tirzepatide and experience symptoms like jaundice, dark urine, or right-sided abdominal pain, seek medical attention immediately. Your doctor should check liver enzymes. If levels are elevated, stopping the drug typically leads to full recovery within a month, but this requires prompt medical intervention and monitoring.

Tirzepatide therapy can cause euglycaemic ketoacidosis in non-diabetic patients, particularly when initiated via online prescribing without rigorous monitoring, due to starvation induced by gastrointestinal side effects.

If you are taking tirzepatide (Mounjaro) for weight loss, especially through an online service, be aware that you can develop a dangerous condition called euglycaemic ketoacidosis. This means your blood becomes acidic due to ketones, even if your blood sugar stays normal. Watch for symptoms like nausea, vomiting, abdominal pain, and fatigue. If you feel unwell, check your ketones if possible and seek medical attention immediately. Do not ignore gastrointestinal side effects as they can lead to starvation and acidosis.

Tirzepatide use is associated with a probable risk of acute pancreatitis, characterized by a strong temporal correlation between drug initiation and symptom onset, and clinical resolution upon discontinuation.

If you are taking tirzepatide and develop severe, persistent upper abdominal pain, nausea, or vomiting, stop the medication immediately and seek medical attention. Do not assume the pain is just from gallstones or indigestion, especially if it started shortly after beginning the drug. Early discontinuation can prevent severe complications.

Consuming soy milk as a post-resistance exercise recovery beverage produces acute circulating sex hormone profiles (testosterone, estrogen, progesterone) equivalent to dairy milk, refuting concerns that soy phytoestrogens negatively impact male anabolic potential.

If you are a male resistance trainer concerned about 'feminizing' effects, you can safely use soy milk as a post-workout recovery drink. This pilot study shows it affects your sex hormones (testosterone, estrogen, progesterone) just as much as dairy milk does, meaning it won't hinder your muscle-building efforts compared to dairy.

Replacing saturated animal fats with polyunsaturated vegetable oils (specifically linoleic acid-rich oils like safflower, canola, and hydrogenated oils) increases all-cause and cardiovascular mortality and accelerates atherosclerosis without lowering LDL-cholesterol in the long term.

Current mainstream guidelines recommending the substitution of animal fats with vegetable oils (high in linoleic acid) may be increasing health risks. The authors suggest restricting toxic vegetable oils (canola, hydrogenated oils) and increasing cholesterol and animal fat intake to non-obese levels, based on evidence that high cholesterol correlates with longevity and vegetable oils may accelerate disease via inflammatory and endocrine mechanisms.

Combining resistance training, a hypercaloric diet, and anabolic androgenic steroids (AAS) produces significantly greater fat-free mass and strength gains with minimal fat gain compared to resistance training and hypercaloric diet alone in drug-free individuals.

For drug-free athletes, maximizing muscle growth requires consistent resistance training, adequate protein (1.6-2.2 g/kg), and a slight caloric surplus. This case study shows that adding AAS can triple fat-free mass gains and significantly boost strength with minimal fat gain, but this comes with legal, health, and ethical risks. For natural athletes, focus on progressive overload, volume (12-16 sets/muscle/week), and nutrition; do not expect the same magnitude of rapid recomposition without pharmacological intervention.

GLP-1 receptor agonists (liraglutide) have unclear clinical benefits in non-obese patients with Heart Failure with Reduced Ejection Fraction (HFrEF).

For non-obese HFrEF patients, GLP-1 agonists like liraglutide may not provide significant weight loss or clear clinical benefits based on current small trials. Consult your doctor about the specific relevance of these treatments for your condition.

Bariatric arterial embolization (BAE) produces modest, transient weight loss (mean 7.0% at 4-5 months, 4.2% at 12 months) in patients with BMI ≥30 who have failed nonoperative management and are ineligible or unwilling to undergo metabolic-bariatric surgery.

If you have obesity (BMI ≥30) and haven't been able to lose weight through diet, exercise, or standard medications, and you are not a candidate for or do not want surgery, BAE might be an option. It involves a minimally invasive procedure to block blood flow to part of the stomach, which reduces hunger hormones. Expect modest weight loss (around 4-7%) over the first year, but it requires ongoing support from a weight management program. It is not a standalone fix and results vary significantly between individuals.

GLP-1 receptor agonists (GLP-1RAs) may indirectly improve autoimmune thyroid disease (AITD) outcomes by reducing systemic inflammation, improving insulin sensitivity, and modulating the gut-thyroid axis, rather than through direct thyroidal effects.

If you have thyroid autoimmunity and are considering GLP-1RAs for weight or diabetes, expect that your thyroid medication doses may need adjustment as you lose weight. The drug likely helps your thyroid health indirectly by lowering body-wide inflammation and improving metabolic health, rather than directly attacking thyroid antibodies. There is no strong evidence yet that it cures thyroid disease, but it is generally safe regarding thyroid cancer risk in humans. Work closely with your endocrinologist to monitor your thyroid levels during weight loss.

Women with non-diabetic obesity experience greater cardiovascular benefits from GLP-1 RAs, particularly regarding heart failure hospitalization and stroke reduction, compared to men.

Women with obesity may derive even greater heart protection from GLP-1 medications than men, especially regarding heart failure prevention. This is particularly true for postmenopausal women who are at higher risk for heart failure with preserved ejection fraction (HFpEF). Discussing your specific heart failure risk with your provider is crucial.

State-of-the-art anti-obesity medications (AOMs) like GLP-1 analogues are highly effective appetite suppressants but require continuous use, as discontinuation leads to inevitable weight regain.

Understand that obesity medications like Semaglutide or Tirzepatide are long-term treatments. Stopping them will likely lead to weight regain. Plan for continuous use as part of your long-term health strategy.

Current randomized controlled trial evidence does not demonstrate a statistically significant increase in thyroid cancer risk with the use of incretin-based therapies (GLP-1RAs and dual GIP/GLP-1RAs).

Current high-quality randomized trial data does not support a claim that GLP-1 or GIP/GLP-1 drugs cause thyroid cancer in the general population. However, the evidence is very low certainty because these trials are too short and too small to rule out a rare, long-term risk. Clinicians should continue prescribing these drugs for their proven benefits while adhering to the FDA boxed warning for patients with a specific family history of medullary thyroid cancer.

Preoperative use of GLP-1 receptor agonists is associated with reduced rates of periprosthetic joint infection (PJI) and hospital readmission in patients undergoing total hip and knee arthroplasty, particularly among those with diabetes or morbid obesity.

If you are taking a GLP-1 RA (like Ozempic or Wegovy) before hip or knee replacement surgery, current evidence suggests it may lower your risk of joint infection and hospital readmission, especially if you have diabetes or obesity. However, because these drugs cause rapid weight loss, your surgical team must carefully monitor your nutritional status (e.g., albumin levels) to ensure you are not malnourished, which could increase complication risks. Do not stop the medication without consulting your surgeon, as the net benefit appears positive in many cases, but close monitoring is essential.

Epitalon, a tetrapeptide, extends cellular lifespan by activating telomerase and lengthening telomeres, while also modulating pineal gland function to restore melatonin synthesis.

Epitalon is an investigational peptide that may extend cellular lifespan by activating telomerase and restoring melatonin production. While animal studies show promising lifespan extension, human data is limited to small studies without long-term safety validation. It is not FDA-approved for anti-aging.

BPC-157 and TB-500 enhance tissue repair and angiogenesis in aged tissues, showing promise in small pilot studies for chronic pain and wound healing.

BPC-157 and TB-500 are peptides that may help heal tissues, tendons, and muscles by promoting blood vessel growth and reducing inflammation. Small studies suggest they can relieve chronic pain and heal wounds, but they are not FDA-approved for these uses, and long-term safety is unknown.